Risk of COVID-19 in Dermatologic Patients on Long-term Immunomodulatory Therapy
Holcomb, Zachary E. ; Santillan, Monica Rosales ; Morss-Walton, Peyton C ; Salian, Prerna ; Her, Min Ji ; Giannotti, Nicole M. ; Kimball, Alexa B. ; Porter, Martina L.
Citations
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Publication Date
Keywords
Dupilumab
IL-17 inhibitor
IL-23 inhibitor
IL12/23 inhibitor
Jak inhibitor
TNF alpha inhibitor
adalimumab
apremilast
biologics
coronavirus
cyclosporine
etanercept
guselkumab
immunosuppression
infliximab
ixekizumab
methotrexate
mycophenolate mofetil
risankizumab
secukinumab
tofacitinib
ustekinumab
Dermatology
Immunotherapy
Infectious Disease
Skin and Connective Tissue Diseases
Virus Diseases
Subject Area
Embargo Expiration Date
Link to Full Text
Abstract
As the COVID-19 pandemic has rapidly spread around the globe, concern has been raised regarding susceptibility of patients on immunomodulatory therapies to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. While general guidance has been put forth, data regarding infection rate and outcomes in immunosuppressed patients is still rare.1 Recent articles, including the work by Gisondi, et al, suggest that outcomes of patients on systemic immunomodulatory therapies infected with SARS-CoV-2 are similar to the general population.2 These findings may relate to the aberrant cytokine and inflammatory responses in severe COVID-19, which may be treated or partially blunted by cytokine-targeted therapy.3 Given the substantial outbreak of COVID-19 in our community, we tested whether, in addition to similar outcomes, patients on systemic immunomodulatory therapy had similar infection rates compared to the general population.
Source
Holcomb ZE, Santillan MR, Morss-Walton PC, Salian P, Her MJ, Giannotti NM, Kimball AB, Porter ML. Risk of COVID-19 in Dermatologic Patients on Long-term Immunomodulatory Therapy. J Am Acad Dermatol. 2020 Jul 1:S0190-9622(20)32099-5. doi: 10.1016/j.jaad.2020.06.999. Epub ahead of print. PMID: 32622141; PMCID: PMC7329682. Link to article on publisher's site